New injectable PrEP set to reshape HIV prevention England and Wales are nearing a landmark decision that could alter the landscape of HIV prevention. A long-acting injectable drug, cabotegravir (CAB-LA), is recommended for use in adults and young people who are HIV-negative, with the aim of reducing new infections. Unlike the routine daily tablets used…